Biosimilar Naming, Interchangeability Policies Must Be Done Soon, House Tells FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Appropriations report sets a deadline, but doesn't include a penalty for missing it as the House had with the opioid guidance last year.